Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Interviews”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9Linked to original sources
PubMed1999

A career of disease prevention, detection and control: an interview with Dr. Denny Donnell, State Epidemiologist of Missouri. Interview by Thomas Eppright, Shane Bradley, Maureen A. Allwood, James R. Slaughter.

Denny Donnell began his tenure as Missouri State Epidemiologist in 1973. Since that time, he has been instrumental in the prevention, detection and control of disease across the state. In this interview he reflects on the path that led him to disease control and he emphasizes the need for further training opportunities for physicians who wish to battle disease beyond the realm of one person at a time.

Epidemiology↗
PubMedDate not supplied

The medical director as educator: an interview with Elizabeth M. Gallup, MD, JD, MBA. Interview by Richard L. Reece.

Richard L. Reece, MD, interviewed Elizabeth M. Gallup, MD, JD, MBA, on July 9, 1999, to talk about the evolving role of the physician executive. Dr. Gallup discusses how medical directors have evolved from a purely clinical role to participating in the business side of medicine as well. The traditional medical director, a Dr. No who denies treatment and watches clinical performance, is now becoming an educator helping physicians to manage their behavior and change their practices based on comparative data. Her book, How Physicians Can Avoid Surrender and Lead Change: Gaining Real Influence in Your Own Health Care Organization Before It's Too Late, (American College of Physician Executives, 1996) promotes acting together as a group if physicians want to stay independent and not become employed. Independent physicians can form IPAs and act together as a group, avoiding some antitrust laws. Unless physicians get together and act as a group, she says, they are doomed to further and further erosion of their economic interests as well as their clinical autonomy.

Health Maintenance Organizations↗
PubMedDate not supplied

Hired, fired, and not retired: an interview with a physician executive who has run the career gauntlet. Interview by Richard L. Reece.

Richard L. Reece, MD, interviewed Robert J. Hudson, MD, on April 24, 2000 to discuss his experiences as a physician executive who has made the career transition from practicing physician to managed care executive to biotech entrepreneur. Along the way, he's hired and fired others, and been fired himself. Painful as it is, many physician executives' career realities include being fired. Organizations, after all, are living organizations--they grow, wither, and molt. And as they molt, organizations shed and regrow new skin. What do physician executives do when they've been fired? They go through their own cycle and retreat, reflect, and re-emerge, often reinventing themselves as they go. An essential part of this process is looking within to plumb likes and dislikes, strengths and weaknesses, nightmares and dreams, and positive and negative experiences. For most executives, out of these experiences has come a circle of friends and a Rolodex. Start by reaching out to the circle, by going through your Rolodex, and you can broadcast the news of your rebirth.

Career Mobility↗
PubMedDate not supplied

The rudiments of an Internet-based health plan for consumers: an interview with John Danaher, MD, MBA. Interview by Richard L. Reece.

Richard L. Reece, MD, interviewed John Danaher, MD, MBA, on August 16, 2000, to discuss how his new company is preparing for the perfect storm--the looming convergence of demanding consumers, defined contributions, and Internet-based health plans. He describes how his firm is putting financial and clinical tools in the hands of consumers and physicians, so consumers can be more enlightened in their health care choices. Danaher says, "We're not about buying goods and services online. We are transforming the way consumers buy health care and seek insurance. We're trying to be a 401 k where people get on, knowing their risk profile and return horizons. We aim to motivate consumers to be proactive in making health care choices. How do we make consumers responsible and motivated enough to take control of managing their health care costs? How well we articulate this call to consumer action will be the key to our success."

Community Participation↗
PubMed2001

High tech the old-fashioned way. An interview with Tom Siebel of Siebel Systems. Interview by Bronwyn Fryer.

There is a growing awareness among corporations that the quality of the customer experience they provide directly affects their bottom line. Many are turning to high-flying software maker Siebel Systems for help in managing those relationships. The young company holds a leadership position in an explosive market-enterprise application software. But customer satisfaction, not dot-com chic, is foremost on the mind of Siebel Systems' founder, chairman, and CEO, Tom Siebel. The buttoned-down Siebel rejects the freewheeling management style and culture that characterize many Silicon Valley companies. As the former CEO of Gain Technology and a former executive at Oracle, Siebel believes in putting customers ahead of technology, discipline ahead of inspiration. In this interview, conducted at the company's San Mateo, California, headquarters, Siebel describes how this obsessive focus on customer satisfaction has been the driving force behind the company's success. He talks about how the organization remains true to its core values: a deep commitment to providing customer satisfaction; responsible fiscal practices that have created a cash-positive business amid today's cash-negative dot-coms; and general professionalism. "The notion of dressing in jeans and a T-shirt to greet the CEO of a major financial institution who just got off the plane from Munich is not acceptable," he says. Siebel Systems rejects the concept of going to war with rivals; instead, the CEO says, the company has forged an ecosystem of partnerships that allows it to support and integrate its own systems with other companies' software products and ultimately ease the customer's software installations. Indeed, Siebel says, the CEO's most important job is to understand what customers need and deliver that.

Commerce↗
PubMedDate not supplied

Physician behavior at the e-technology/learning intersection: an interview with Elliott Masie. Interview by Richard L. Reece.

Richard L. Reece, MD, interviewed Elliott Masie on January 16, 2001, to talk about the Internet learning world--that vast intersection of e-technology, learning, and human behavior. He describes how he looks beyond the hype of technology into how human beings behave and what they crave in social experiences. The real question, he says, is how do we have knowledge experiences and blend them with social experiences to achieve the optimal mix? Masie emphasizes, "The magic of learning is in the mix--what happens online and then what happens informally when we have a cup of coffee with a colleague." He continues, "Many of the capital market folks hate to hear about the human element, because they want to believe we'll be able to do everything from our PCs. But that's not how humans behave. It's the mixture that gets results. That's where the real excitement occurs."

Attitude of Health Personnel↗
PubMed2001

Mastering the value chain. An interview with Mark Levin of Millennium Pharmaceuticals. Interview by David Champion.

As today's business leaders are all too aware, a new scientific or technological break-through can quickly transform an industry's competitive landscape. The upheaval is often traumatic for the companies involved, forcing them to rethink their strategies and redefine their boundaries. But an industry in flux also creates vast opportunities. To seize them, companies must see how the current upheavals will affect the future distribution of profits--and then reinvent themselves to capitalize on the new sources of value. In this interview with HBR senior editor David Champion, Mark Levin, the founder and CEO of Millennium Pharmaceuticals, describes his vision of the future of the pharmaceutical industry in the wake of the genetics revolution and new technologies that have altered the economics of drug development. No company, he argues, will create serious long-term value by staying in just one or two stages of the value of chain. That's why Millennium, which started out doing basis research into genes and proteins and selling its findings to pharmaceutical giants, has moved downstream - toward the patients who actually use and pay for the drugs. He explains why the research end has become less lucrative than the more mechanical tasks of identifying, testing, and manufacturing molecules. Levin talks about the changes Millennium has undergone since its inception in 1993-from 30 workers to more than 1,000, and from one end of the value chain to the other. He discusses the company's cultural transformations as well as the partnerships and acquisitions that have helped millennium become involved in every stage of the chain-from gene to patient. Levin's vigorous approach to balancing long-term strategy with short-term tactics offers important lessons to any executive facing an industry upheaval.

Drug Design↗
PubMed1994

Interview with Dr. Oleg Atkov [interview by Winston Huff].

Last summer International Space University (ISU) was held in Huntsville, Alabama. Leading international space experts came to take part in the activities. Dr. Oleg Atkov, a Russian cardiologist who was also a cosmonaut for eight months in 1984, has extensive experience in cardiovascular medicine and first-hand experience in issues of life support, making him a valuable resource. He also serves on the Journal's Advisory Board. Winston Huff took advantage of the unique opportunity of having Valery Aksamentov, Paul Wieland, and Dr. Atkov together in Huntsville to conduct a general discussion of issues important to those studying life support. Dr. Valery Aksamentov was involved for many years in the development of the Russian life support systems. Dr. Aksamentov now leads the only university program specializing in life support at the University of Alabama in Huntsville. His command of both languages and his technical knowledge were critical to the success of this discussion. Paul Wieland from NASA Marshall Space Flight Center is involved with the development of the life support systems for the space station. He and Dr. Aksamentov are topic coordinators for the Journal. The following interview was conducted at the University of Alabama in Huntsville on August 16, 1993.

Ecological Systems, Closed↗
PubMed2002

Randomised controlled trials in nursing and midwifery: an interview with Maralyn Foureur. Interview by Pamela J. Wood.

Randomised controlled trials are considered to be one of the best research designs for determining effective care in the clinical setting. Relatively few randomised controlled trials, however, have been carried out in nursing or midwifery practice, so few examples of the practical realities of this research methodology are readily accessible. This is the sixth article in a series based on interviews with nursing and midwifery researchers, designed to offer the beginning researcher a first-hand account of the experience of using particular methodologies. This article focuses on the randomised controlled trial as experienced by Maralyn Foureur (RGON, RM, BA, Grad Dip Clin Epidem, PhD) who used this methodology to demonstrate the effectiveness of a continuity of care model in midwifery practice.

Continuity of Patient Care↗
PubMed2000

HMO, insurance policies threaten HIV care: interview with Dr. X. Interview by John S. James.

Many health plans use various means to discourage HIV specialty care--even though such care clearly benefits patients, and costs less, compared to non-specialist care--in order to avoid attracting expensive patients into their plans. This problem is much worse in HIV than in cancer and other catastrophic illnesses with more established specialties. AIDS Treatment News interviewed an AIDS doctor who provides details--but who must remain anonymous to avoid retaliation by some of the health plans.

Adult↗
PubMed2000

Nutrition and HIV infection: experience in Zimbabwe: interview with Lynde Francis. Interview by John S. James.

For years Lynde Francis has run an AIDS service organization in Harare, Zimbabwe, where few patients can afford antiretrovirals, so nutritional improvement is often the only treatment available. In this interview she explains what she has found to be helpful. While specific nutritional advice will vary, depending on many factors, we believe that readers should be aware of this treatment experience.

Developing Countries↗
PubMed2003

Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James.

We asked a leading AIDS physician to summarize some of the important treatment messages for physicians and patients, from the 10th Conference on Retroviruses and Opportunistic Infections, a major scientific meeting. Part 1 of the 2-part interview looks a starting antiretroviral therapy (including tenofovir vs. d4T, and efavirenz vs. nevirapine), new protease-inhibitor information, and antiretroviral drug toxicity.

Anti-HIV Agents↗
PubMed2002

HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.

We asked a leading HIV physician to summarize some of the treatment issues that clinicians are now looking at after the Barcelona conference. Topics in this interview include: Tenofovir, including first-line therapy; The shift from protease inhibitors to non-nucleoside RT inhibitors, for many but not all patients; Benefits of once-a-day regimens; Lipodystrophy, and strategies for avoiding or reducing it; Viral resistance testing; T-20; Prevention--including danger of superinfection with a new HIV strain.

Anti-HIV Agents↗
PubMedDate not supplied

An interview with Nancy L. Johnson and Patricia Schroeder. Interview by Carmella A. Bocchino.

In the U.S. Congress--440 members in the House and 100 members in the Senate--only 31 are women (29 House and 2 Senate members). This year over 100 women are seeking seats in the Congress, many are campaigning for governor, and still others are running for state and local offices. Women candidates are generally seen as outsiders who symbolize change and inspire a new vision for the future. This interview highlights two incumbent members of the House of Representatives, Nancy L. Johnson (R-CT) and Patricia Schroeder (D-CO), and their views on women's health, family medical leave, and future changes in the U.S. health care system.

Health Policy↗
PubMed2004

How to restore the fiduciary relationship. An interview with Eliot Spitzer. Interview by Louise O'Brien.

Eliot Spitzer's investigations into the mutual fund and investment-banking industries have made the New York State attorney general the de facto flag bearer of corporate reform. His exposure of conflicts of interest between investment bankers and research analyst in Wall Street firms led to the $1.4 billion global settlement between regulators and banking houses in 2003. In this interview, Spitzer describes the challenge of protecting public markets from conflicts of interest, paying particular attention to how such conflicts get institutionalized in an industry. "The cases that have gotten me and my fellow regulators most upset are the ones where we've seen senior management being tolerant of rank abuses," he says. "Because then you know that the entire structure is rotten." He also points the finger squarely at boards, maintaining that board members are drawn from pools of company and industry insiders. He cites "a void in values in a lot of boardrooms," holding up executive compensation as a powerful example. "Board compensation committees ... are self-selected and interwoven--it's a rigged marketplace." He continues, "It would be interesting to see what the world would look like if CEO pay packages had to be submitted to shareholder votes." Spitzer suggests that what's really needed is for all business leaders to reinstill throughout their organizations the critical notion of a fiduciary duty--whether it is to the shareholder or to the customer. Using the mutual fund industry as an example, he also contrasts the value of enforcement with that of regulation and articulates an important--and surprisingly limited--role for government in protecting free markets.

Administrative Personnel↗
PubMedDate not supplied

A time for growth: an interview with Amgen CEO Kevin Sharer. Interview by Paul Hemp.

Fast growth is a nice problem to have--but a hard one to manage well. In this interview, Kevin Sharer, the CEO of biotech giant Amgen, talks about the special challenges leaders face when their companies are on a roll. Sharer, who was also head of marketing at pre-WorldCom MCI and a division head and a staff assistant to Jack Welch at GE, offers insights drawn from his own experience--and from his own self-proclaimed blunders: "I learned the hard way that you need to become credible and enlist support inside the company before you start trying to be a change agent. If you think you're going to make change happen simply by force of personality or position or intellect, you'd better think again." And change there was: Under Sharer's leadership, Amgen overhauled its management team, altered its culture, and launched a couple of blockbuster products. How do chief executives survive in that kind of dizzying environment? "A CEO must always be switching between different altitudes--tasks of different levels of abstraction and specificity," Sharer says. "You might need to spend time working on a redesign of your organizational structure and then quickly switch to drafting a memo to all employees aimed at reinforcing one of the company's values." Having a supportive and capable top team is also key: "A top management team is the most revealing window into a CEO's style, values, and aspirations.... If you don't have the right top team, you won't have the right tiers below them. [The] A players won't work for B players. Maybe with a company like GE, the reputation of the company is so strong that it can attract top people to work for weaker managers. In a new company like Amgen, that won't happen."

Administrative Personnel↗
PubMed2004

Saving AIDS conferences online: interview with Sister Mary Elizabeth, founder of AEGiS. Interview by John S. James.

Some of the most important AIDS conferences are not online, and even the U.S. National Library of Medicine and the conference organizers do not have a paper or electronic copy of the abstracts presented. Some may be lost forever. But they could be saved if a copy can be found, and you might be able to help. Here we interview the founder of AEGIS (www.aegis.org/), the well-known AIDS database that has done critically important work in preserving conferences as well as making AIDS news and other information available around the world.

Acquired Immunodeficiency Syndrome↗